Targeting hemoglobin (Hb) values of 13 g/dL or higher reduces progression of chronic allograft nephropathy in kidney transplant recipients, a prospective study suggests.
After two years of treatment with epoetin beta to keep Hb levels in the normal range of 13.0 to 15.0 g/dL (63 kidney-transplant recipients) or at a lower concentration of 10.5 to 11.5 g/dL (62 recipients), 4.8% of patients with completely corrected anemia developed kidney failure, compared with 21% of those with partially corrected anemia.
Gabriel Choukroun, MD, PhD, and co-investigators also noted in Journal of the American Society of Nephrology that 94.6% of transplanted kidneys in patients with completely corrected anemia were functional, compared with 80% in the partial-correction group.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.